Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of oncology and immunotherapy products. Headquartered in Agoura Hills, California, the company's mission is to address high-unmet-need cancers and rare pediatric indications through innovative, late-stage therapeutic candidates.

The company's pipeline includes several key drug candidates. OT-101, a first-in-class anti-TGF-β RNA therapeutic, is in clinical trials for solid tumors such as pancreatic cancer and glioblastoma, and also shows activity against SARS-CoV-2. Other products include OXi4503, a vascular disrupting agent for acute myeloid leukemia and myelodysplastic syndromes, and CA4P, another vascular disrupting agent for advanced metastatic melanoma. Oncotelic also develops AL-101 for neurological and sexual dysfunctions, and Artemisinin for COVID-19. The company is also advancing nanoparticle products through its Deciparticle™ platform.

Led by CEO Dr. Vuong Trieu, who holds numerous patents, Oncotelic emphasizes a partnership-driven strategy to advance its pipeline. The company holds a 45% interest in GMP Bio, a joint venture that contributes significantly to its balance sheet through independent valuations and is advancing a complementary pipeline of therapeutic candidates. Oncotelic leverages its proprietary AI-enabled PDAOAI platform to support drug development. The company is publicly traded on the OTCQB Market under the ticker OTLC and has received Rare Pediatric Disease Designations from the FDA for some of its candidates.